可持续的抗微生物药物耐药性监测:建立全球筹资机制的时机已到
抗微生物药物耐药性(AMR)预计到2050年将成为领先的感染性死亡原因,超过疟疾、HIV和结核病之和。WHO全球AMR行动计划五大目标之一是加强监测与研究。研究估算低收入和中等收入国家(LMICs)标准国家AMR监测系统的持续成本:46个LMICs的成本超过其国内政府卫生总支出(GGHE-D)的2%,其中28国超过5%,若无长期全球筹资机制则不可持续。
要点
- AMR预计到2050年成为领先感染性死因,超过疟疾、HIV和结核病之和。
- 加强诊断与监测的努力在多数低资源环境中若无持续资金支持则难以持续。
- 46个LMICs标准国家AMR监测系统成本超其GGHE-D的2%,其中28国超5%。
核心结论
- 在低收入和中等收入国家,标准国家AMR监测系统的持续成本若无长期全球筹资机制则不可持续。
研究设计与样本
- 研究估算了低收入和中等收入国家(LMICs)标准国家AMR监测系统的持续成本。
主要发现
- 对于46个LMICs,标准国家AMR监测系统的成本超过其国内政府卫生总支出(GGHE-D)的2%。
- 在46个LMICs中,有28个国家的成本超过其GGHE-D的5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antimicrobial resistance (AMR) is predicted to outstrip malaria, HIV, and tuberculosis combined as the leading infectious cause of death by 2050. Strengthening the knowledge and evidence base for AMR with surveillance and research is one of the five main objectives of the WHO Global Action Plan on AMR. While recent efforts to strengthen diagnosis and surveillance have been encouraging, these are unlikely to be sustainable without continued funding support in most low-resource settings. We estimated the continued costs of a standard national AMR surveillance system in low-income and middle-income countries (LMICs). For 46 LMICs, the costs would account for more than 2% of their total domestic general government health expenditure (GGHE-D), and for 28 of these countries, the costs are more than 5% of their total GGHE-D. This high cost is not sustainable without a long-term global financing mechanism.
引用
- Painter C, Limmathurotsakul D, Roberts T, et al. Sustainable antimicrobial resistance surveillance: time for a global funding mechanism. Lancet Infect Dis. 2024. PMID: 39706207. doi:10.1016/S1473-3099(24)00649-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。